Pharma Business - March 5, 2015
AstraZeneca to Open R&D Site
AstraZeneca is planning to move its antibiotic research and development business into a standalone company at a cost of about $40 million. The plan will affect about 95 people at its facility in Waltham, MA. The focus of the new company will be research and development of AstraZeneca’s early-stage antibiotic pipeline. This will include AZD0914, […]
Collaboration - February 26, 2015
AstraZeneca, Orca Sign Pact
British biotech startup Orca got $122.5 million from AstraZeneca PLC after the two companies signed a three-year research agreement to develop Orca’s retinoic acid-related orphan nuclear receptor gamma inhibitors. Orca is slated to receive upfront and milestone payments from AstraZeneca, depending on the success of its RORϒ inhibitors in the program. There is potential for […]
Acquisition - February 19, 2015
AZ Books UK–Sweden Flight
Beginning in March, AstraZeneca will pay for Scandinavian airline Sun Air to make the one-hour flight from Cambridge to Gothenburg’s Landvetter airport Monday to Thursday mornings, and return in the early evening, to link the company’s two research hubs. AstraZeneca has agreed to pay for 20 seats on each flight, but the remaining 12 will be open […]
Agreement - February 18, 2015
Astra to Pay $7.9M U.S. Fine
AstraZeneca has agreed to pay American authorities $7.9 million to settle allegations the company engaged in a kickback scheme with Medco Health Solutions, a pharmacy benefit managers, to boost sales of its heartburn medication Nexium, according to a BioSpace article. “AstraZeneca embarked on this course of unlawful conduct knowing it would lead to the submission […]
Acquisition - February 18, 2015
AstraZeneca to Acquire Actavis’ Branded Respiratory Side in U.S., Canada
AstraZeneca plans to acquire the rights to Actavis’ branded respiratory business in the U.S. and Canada for an initial consideration of $600 million on completion and low single-digit royalties above a certain revenue threshold. When the transaction is finalized, AstraZeneca will own the development and commercial rights in the US and Canada to TudorzaTM PressairTM […]
Companies - February 18, 2015
AZ Shareholders to Nominate Non-Executive Director
Cornelia Bargmann will be nominated by AstraZeneca shareholders as a non-executive director at the company’s annual general meeting on April 24. The Board of Directors is also proposing the appointment of Bargmann to AstraZeneca’s Science Committee. John Varley, senior independent non-executive director, and Nancy Rothwell, non-executive director, both intend to retire from the Board of […]
